Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters

Yasutaka Maeda, Toyoshi Inoguchi, Ryoko Takei, Fumi Sawada, Shuji Sasaki, Masakazu Fujii, Kunihisa Kobayashi, Hidenori Urata, Akira Nishiyama, Ryoichi Takayanagi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Accumulating evidence suggests that the intrarenal renin-angiotensin system may be involved in the progression of diabetic nephropathy. Chymase is a potent local angiotensin II-forming enzyme in several species, including humans and hamsters. However, the pathophysiological role of chymase is not fully understood. Here, we report a causal role of chymase in diabetic nephropathy and the therapeutic effectiveness of chymase inhibition. In the present study, renal chymase expression was markedly upregulated in streptozotocin-induced diabetic hamsters. Oral administration of a specific chymase inhibitor, TEI-F00806, completely ameliorated proteinuria, the overexpression of transforming growth factor-β and fibronectin in glomeruli, and renal mesangial expansion, by normalizing the increase in intrarenal angiotensin II levels in diabetic hamsters independently of blood pressure levels. In contrast, ramipril did not show such sufficient effects. These effects occurred in parallel with improvements in superoxide production and expression of NAD(P)H oxidase components [NAD(P)H oxidase 4 and p22phox] in glomeruli. This study showed for the first time that chymase inhibition may protect against elevated intrarenal angiotensin II levels, oxidative stress, and renal dysfunction in diabetes. These findings suggest that chymase offers a new therapeutic target for diabetic nephropathy.

Original languageEnglish
Pages (from-to)F1328-F1338
JournalAmerican Journal of Physiology - Renal Physiology
Volume299
Issue number6
DOIs
Publication statusPublished - Dec 1 2010

Fingerprint

Chymases
Cricetinae
Oxidative Stress
Kidney
Diabetic Nephropathies
Angiotensin II
NADPH Oxidase
Ramipril
Transforming Growth Factors
Renin-Angiotensin System
Streptozocin
Proteinuria
Fibronectins
Renin
Superoxides
Oral Administration
Blood Pressure

All Science Journal Classification (ASJC) codes

  • Physiology
  • Urology

Cite this

Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. / Maeda, Yasutaka; Inoguchi, Toyoshi; Takei, Ryoko; Sawada, Fumi; Sasaki, Shuji; Fujii, Masakazu; Kobayashi, Kunihisa; Urata, Hidenori; Nishiyama, Akira; Takayanagi, Ryoichi.

In: American Journal of Physiology - Renal Physiology, Vol. 299, No. 6, 01.12.2010, p. F1328-F1338.

Research output: Contribution to journalArticle

Maeda, Y, Inoguchi, T, Takei, R, Sawada, F, Sasaki, S, Fujii, M, Kobayashi, K, Urata, H, Nishiyama, A & Takayanagi, R 2010, 'Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters', American Journal of Physiology - Renal Physiology, vol. 299, no. 6, pp. F1328-F1338. https://doi.org/10.1152/ajprenal.00337.2010
Maeda, Yasutaka ; Inoguchi, Toyoshi ; Takei, Ryoko ; Sawada, Fumi ; Sasaki, Shuji ; Fujii, Masakazu ; Kobayashi, Kunihisa ; Urata, Hidenori ; Nishiyama, Akira ; Takayanagi, Ryoichi. / Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. In: American Journal of Physiology - Renal Physiology. 2010 ; Vol. 299, No. 6. pp. F1328-F1338.
@article{9d89675a72bc4139b02572d5d2d52a24,
title = "Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters",
abstract = "Accumulating evidence suggests that the intrarenal renin-angiotensin system may be involved in the progression of diabetic nephropathy. Chymase is a potent local angiotensin II-forming enzyme in several species, including humans and hamsters. However, the pathophysiological role of chymase is not fully understood. Here, we report a causal role of chymase in diabetic nephropathy and the therapeutic effectiveness of chymase inhibition. In the present study, renal chymase expression was markedly upregulated in streptozotocin-induced diabetic hamsters. Oral administration of a specific chymase inhibitor, TEI-F00806, completely ameliorated proteinuria, the overexpression of transforming growth factor-β and fibronectin in glomeruli, and renal mesangial expansion, by normalizing the increase in intrarenal angiotensin II levels in diabetic hamsters independently of blood pressure levels. In contrast, ramipril did not show such sufficient effects. These effects occurred in parallel with improvements in superoxide production and expression of NAD(P)H oxidase components [NAD(P)H oxidase 4 and p22phox] in glomeruli. This study showed for the first time that chymase inhibition may protect against elevated intrarenal angiotensin II levels, oxidative stress, and renal dysfunction in diabetes. These findings suggest that chymase offers a new therapeutic target for diabetic nephropathy.",
author = "Yasutaka Maeda and Toyoshi Inoguchi and Ryoko Takei and Fumi Sawada and Shuji Sasaki and Masakazu Fujii and Kunihisa Kobayashi and Hidenori Urata and Akira Nishiyama and Ryoichi Takayanagi",
year = "2010",
month = "12",
day = "1",
doi = "10.1152/ajprenal.00337.2010",
language = "English",
volume = "299",
pages = "F1328--F1338",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters

AU - Maeda, Yasutaka

AU - Inoguchi, Toyoshi

AU - Takei, Ryoko

AU - Sawada, Fumi

AU - Sasaki, Shuji

AU - Fujii, Masakazu

AU - Kobayashi, Kunihisa

AU - Urata, Hidenori

AU - Nishiyama, Akira

AU - Takayanagi, Ryoichi

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Accumulating evidence suggests that the intrarenal renin-angiotensin system may be involved in the progression of diabetic nephropathy. Chymase is a potent local angiotensin II-forming enzyme in several species, including humans and hamsters. However, the pathophysiological role of chymase is not fully understood. Here, we report a causal role of chymase in diabetic nephropathy and the therapeutic effectiveness of chymase inhibition. In the present study, renal chymase expression was markedly upregulated in streptozotocin-induced diabetic hamsters. Oral administration of a specific chymase inhibitor, TEI-F00806, completely ameliorated proteinuria, the overexpression of transforming growth factor-β and fibronectin in glomeruli, and renal mesangial expansion, by normalizing the increase in intrarenal angiotensin II levels in diabetic hamsters independently of blood pressure levels. In contrast, ramipril did not show such sufficient effects. These effects occurred in parallel with improvements in superoxide production and expression of NAD(P)H oxidase components [NAD(P)H oxidase 4 and p22phox] in glomeruli. This study showed for the first time that chymase inhibition may protect against elevated intrarenal angiotensin II levels, oxidative stress, and renal dysfunction in diabetes. These findings suggest that chymase offers a new therapeutic target for diabetic nephropathy.

AB - Accumulating evidence suggests that the intrarenal renin-angiotensin system may be involved in the progression of diabetic nephropathy. Chymase is a potent local angiotensin II-forming enzyme in several species, including humans and hamsters. However, the pathophysiological role of chymase is not fully understood. Here, we report a causal role of chymase in diabetic nephropathy and the therapeutic effectiveness of chymase inhibition. In the present study, renal chymase expression was markedly upregulated in streptozotocin-induced diabetic hamsters. Oral administration of a specific chymase inhibitor, TEI-F00806, completely ameliorated proteinuria, the overexpression of transforming growth factor-β and fibronectin in glomeruli, and renal mesangial expansion, by normalizing the increase in intrarenal angiotensin II levels in diabetic hamsters independently of blood pressure levels. In contrast, ramipril did not show such sufficient effects. These effects occurred in parallel with improvements in superoxide production and expression of NAD(P)H oxidase components [NAD(P)H oxidase 4 and p22phox] in glomeruli. This study showed for the first time that chymase inhibition may protect against elevated intrarenal angiotensin II levels, oxidative stress, and renal dysfunction in diabetes. These findings suggest that chymase offers a new therapeutic target for diabetic nephropathy.

UR - http://www.scopus.com/inward/record.url?scp=78649951030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649951030&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00337.2010

DO - 10.1152/ajprenal.00337.2010

M3 - Article

C2 - 20881036

AN - SCOPUS:78649951030

VL - 299

SP - F1328-F1338

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 6

ER -